Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.

Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M; Pediatric AIDS Clinical Trials Group.

Antimicrob Agents Chemother. 2007 Dec;51(12):4297-302. Epub 2007 Sep 24.

2.

Developmental pharmacokinetic changes of Lamivudine in infants and children.

Tremoulet AH, Nikanjam M, Cressey TR, Chokephaibulkit K, McKinney R, Mirochnick M, Capparelli EV.

J Clin Pharmacol. 2012 Dec;52(12):1824-32. doi: 10.1177/0091270011426563. Epub 2011 Dec 16.

3.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Review.

PMID:
21735394
4.

Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?

Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Van De Perre P, Tréluyer JM, Msellati P, Urien S.

Antimicrob Agents Chemother. 2010 Aug;54(8):3280-6. doi: 10.1128/AAC.00306-10. Epub 2010 Jun 1.

5.

Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents.

Bouazza N, Hirt D, Blanche S, Frange P, Rey E, Tréluyer JM, Urien S.

Antimicrob Agents Chemother. 2011 Jul;55(7):3498-504. doi: 10.1128/AAC.01622-10. Epub 2011 May 16.

6.

Clinical pharmacokinetics of lamivudine.

Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE.

Clin Pharmacokinet. 1999 Jan;36(1):41-66. Review.

PMID:
9989342
7.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510. Review. Update in: Cochrane Database Syst Rev. 2011;(7):CD003510.

PMID:
17253490
8.

Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.

Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Veloso VG, Rossi S, Moye J, Bryson Y, Mofenson L, Camarca M, Watts DH; NICHD HPTN 040/PACTG 1043 PROTOCOL Team.

Pediatr Infect Dis J. 2011 Sep;30(9):769-72. doi: 10.1097/INF.0b013e3182242950.

9.

A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.

Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P, Plipat N, Sirisanthana V, Prasitsuebsai W, Hongsiriwan S, Chotpitayasunondh T, Eksaengsri A, Toye M, Smith ME, McIntosh K, Capparelli E, Yogev R; IMPAACT P1056 Team.

Pediatr Infect Dis J. 2010 Oct;29(10):940-4. doi: 10.1097/INF.0b013e3181e2189d.

10.

Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.

Fletcher CV, Yogev R, Nachman SA, Wiznia A, Pelton S, McIntosh K, Stanley K.

Pharmacotherapy. 2004 Apr;24(4):453-9.

PMID:
15098798
11.

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.

Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, Goodwin C, Harrigan PR, Moore KH, Stone C, Plumb R, Johnson MA.

J Infect Dis. 1998 Nov;178(5):1327-33.

12.

Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.

Piana C, Zhao W, Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, Della Pasqua O.

Br J Clin Pharmacol. 2014 May;77(5):861-72. doi: 10.1111/bcp.12247.

13.

Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.

Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Ferrier A, Chintu C, Walker AS, Gibb DM, Burger DM.

AIDS. 2012 Sep 10;26(14):1795-800. doi: 10.1097/QAD.0b013e32835705fd.

PMID:
22739394
14.

Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.

Wade NA, Unadkat JD, Huang S, Shapiro DE, Mathias A, Yasin S, Ciupak G, Watts DH, Delke I, Rathore M, Hitti J, Frenkel L, Samelson R, Smith ME, Mofenson L, Burchett SK.

J Infect Dis. 2004 Dec 15;190(12):2167-74. Epub 2004 Nov 10.

15.

Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children.

Mueller BU, Lewis LL, Yuen GJ, Farley M, Keller A, Church JA, Goldsmith JC, Venzon DJ, Rubin M, Pizzo PA, Balis FM.

Antimicrob Agents Chemother. 1998 Dec;42(12):3187-92.

16.

Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials.

Moore KH, Yuen GJ, Hussey EK, Pakes GE, Eron JJ Jr, Bartlett JA.

Antimicrob Agents Chemother. 1999 Dec;43(12):3025-9.

17.

Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring.

Zhang C, Denti P, van der Walt JS, Ren Y, Smith P, Karlsson MO, McIlleron H.

Ther Drug Monit. 2012 Aug;34(4):481-4. doi: 10.1097/FTD.0b013e31825c6067.

PMID:
22722777
18.

Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.

Zhao W, Cella M, Della Pasqua O, Burger D, Jacqz-Aigrain E; Pediatric European Network for Treatment of AIDS (PENTA) 15 study group.

Br J Clin Pharmacol. 2012 Apr;73(4):641-50. doi: 10.1111/j.1365-2125.2011.04121.x.

19.

Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.

Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, Kolladarungkri T, Vanprapar N.

AIDS. 2005 Sep 23;19(14):1495-9.

PMID:
16135903
20.

Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.

Chadwick EG, Rodman JH, Britto P, Powell C, Palumbo P, Luzuriaga K, Hughes M, Abrams EJ, Flynn PM, Borkowsky W, Yogev R; PACTG Protocol 345 Team.

Pediatr Infect Dis J. 2005 Sep;24(9):793-800.

PMID:
16148846
Items per page

Supplemental Content

Write to the Help Desk